Skip to main content

Type 1 Diabetes News

Type 1 Diabetes is a chronic condition in which your body loses the ability to produce insulin, which is necessary for most cells to convert food into energy and regulate blood sugar levels. 

Includes insulin dose advisor software; plus, a new Novo Nordisk connected Echo insulin pen to debut in Europe later this year
What it’s about, how to get a free copy, and three myths I want to bust
The lame food advice at Adam Brown's diagnosis, why it didn’t work, and Adam's #1 Bright Spot solution
Research presented at EASD 2017 showcased drugs, both new and old, that improve blood sugar management, weight loss, heart health, and even blood pressure
Get your copy at diaTribe.org/BrightSpots for free or name-your-own-price
iPhone users will be able to share insulin dose data between apps, paving way for ecosystem with smart pens and connected pumps
Kerri Sparling on what it’s like to (attempt) balance raising young kids with managing diabetes – and how kids can be the best diabetes motivators
How to overcome the most frustrating diabetes landmine
Major win to complement Lilly’s partnership with Dr. Ed Damiano and the Bionic Pancreas team; insulin-only pivotal trial in late 2017/early 2018
People with type 1 or type 2 diabetes on intensive insulin therapy can qualify. A major win for the diabetes community following years of patient advocacy!
The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations
Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017
The 2017 Patient Voices Contest is currently open; winners will receive a full scholarship to attend the 2017 DiabetesMine Innovation Summit in Palo Alto
New apps and software updates from mySugr, Insulia, One Drop, as well as food and weight loss apps
Tidepool, the software nonprofit that collects data from diabetes devices, announces a major new project to drive better research and products from real-world data
A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM
Cash-pay strips with good accuracy and co-pay programs to save money
A decision on Novo Nordisk’s faster-acting mealtime insulin is expected in late 2017; also launched in Canada, Germany, and the UK, and coming soon to more European...
With Roche’s support, mySugr will expand to more countries and will even begin offering a new package with unlimited test strips and diabetes coaching through German...
Launch by end of 2017 in major pharmacies at lower price than other CGMs; No fingerstick calibration needed, 10-day wear, 12-hour warmup

Pages